{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:06:04Z","timestamp":1779915964827,"version":"3.53.1"},"reference-count":65,"publisher":"Portland Press Ltd.","issue":"3","license":[{"start":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T00:00:00Z","timestamp":1644537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,2,11]]},"abstract":"<jats:p>The extracellular signal-regulated kinase 1\/2 (ERK1\/2) cascade promotes cardiomyocyte hypertrophy and is cardioprotective, with the three RAF kinases forming a node for signal integration. Our aims were to determine if BRAF is relevant for human heart failure, whether BRAF promotes cardiomyocyte hypertrophy, and if Type 1 RAF inhibitors developed for cancer (that paradoxically activate ERK1\/2 at low concentrations: the \u2018RAF paradox') may have the same effect. BRAF was up-regulated in heart samples from patients with heart failure compared with normal controls. We assessed the effects of activated BRAF in the heart using mice with tamoxifen-activated Cre for cardiomyocyte-specific knock-in of the activating V600E mutation into the endogenous gene. We used echocardiography to measure cardiac dimensions\/function. Cardiomyocyte BRAFV600E induced cardiac hypertrophy within 10\u2005d, resulting in increased ejection fraction and fractional shortening over 6 weeks. This was associated with increased cardiomyocyte size without significant fibrosis, consistent with compensated hypertrophy. The experimental Type 1 RAF inhibitor, SB590885, and\/or encorafenib (a RAF inhibitor used clinically) increased ERK1\/2 phosphorylation in cardiomyocytes, and promoted hypertrophy, consistent with a \u2018RAF paradox' effect. Both promoted cardiac hypertrophy in mouse hearts in vivo, with increased cardiomyocyte size and no overt fibrosis. In conclusion, BRAF potentially plays an important role in human failing hearts, activation of BRAF is sufficient to induce hypertrophy, and Type 1 RAF inhibitors promote hypertrophy via the \u2018RAF paradox'. Cardiac hypertrophy resulting from these interventions was not associated with pathological features, suggesting that Type 1 RAF inhibitors may be useful to boost cardiomyocyte function.<\/jats:p>","DOI":"10.1042\/bcj20210615","type":"journal-article","created":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T07:30:33Z","timestamp":1644564633000},"page":"401-424","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cardiomyocyte BRAF and type 1 RAF inhibitors promote cardiomyocyte and cardiac hypertrophy in mice\n                    <i>in vivo<\/i>"],"prefix":"10.1042","volume":"479","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5658-0708","authenticated-orcid":false,"given":"Angela","family":"Clerk","sequence":"first","affiliation":[{"name":"School of Biological Sciences, University of Reading, Reading, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5557-3549","authenticated-orcid":false,"given":"Daniel N.","family":"Meijles","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Sciences Institute, St. George's University of London, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Hardyman","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, University of Reading, Reading, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Fuller","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, University of Reading, Reading, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia P.","family":"Chothani","sequence":"additional","affiliation":[{"name":"Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore City, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Cull","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, University of Reading, Reading, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna T.E.","family":"Cooper","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Sciences Institute, St. George's University of London, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajed O.","family":"Alharbi","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, University of Reading, Reading, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Vanezis","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, U.K."},{"name":"MRC London Institute of Medical Sciences, Imperial College London, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne E.","family":"Felkin","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, U.K."},{"name":"Cardiovascular Research Centre, Royal Brompton and Harefield Hospitals, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomais","family":"Markou","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, University of Reading, Reading, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel J.","family":"Leonard","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, University of Reading, Reading, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer W.","family":"Shaw","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, University of Reading, Reading, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen J.L.","family":"Rackham","sequence":"additional","affiliation":[{"name":"Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore City, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart A.","family":"Cook","sequence":"additional","affiliation":[{"name":"Program in Cardiovascular and Metabolic Disorders, Duke-National University of Singapore Medical School, Singapore City, Singapore"},{"name":"MRC London Institute of Medical Sciences, Imperial College London, London, U.K."},{"name":"National Heart Centre Singapore, Singapore City, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter E.","family":"Glennon","sequence":"additional","affiliation":[{"name":"University Hospitals Coventry and Warwickshire, University Hospital Cardiology Department, Clifford Bridge Road, Coventry, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary N.","family":"Sheppard","sequence":"additional","affiliation":[{"name":"CRY Cardiovascular Pathology Department, St. George's Healthcare NHS Trust, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Sembrat","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Critical Care Medicine, and Dorothy P & Richard P Simmons Center for Interstitial Lung Disease, Department of Medicine, University of Pittsburgh, Pittsburgh, U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Rojas","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy and Critical Care Medicine, and Dorothy P & Richard P Simmons Center for Interstitial Lung Disease, Department of Medicine, University of Pittsburgh, Pittsburgh, U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F.","family":"McTiernan","sequence":"additional","affiliation":[{"name":"Heart, Lung, Blood Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Barton","sequence":"additional","affiliation":[{"name":"National Heart and Lung Institute, Imperial College London, London, U.K."},{"name":"Cardiovascular Research Centre, Royal Brompton and Harefield Hospitals, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"Sugden","sequence":"additional","affiliation":[{"name":"School of Biological Sciences, University of Reading, Reading, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2022,2,11]]},"reference":[{"key":"2022021112294279400_BCJ-2021-0615C1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1152\/physrev.00032.2006","article-title":"Cardiac myocyte cell cycle control in development, disease, and regeneration","volume":"87","year":"2007","journal-title":"Physiol. Rev."},{"key":"2022021112294279400_BCJ-2021-0615C2","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1161\/01.RES.0000077012.11088.BC","article-title":"Phenotyping hypertrophy: eschew obfuscation","volume":"92","year":"2003","journal-title":"Circ. Res."},{"key":"2022021112294279400_BCJ-2021-0615C3","doi-asserted-by":"publisher","first-page":"4319","DOI":"10.1111\/bph.14363","article-title":"Programmed necrosis in cardiomyocytes: mitochondria, death receptors and beyond","volume":"176","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"2022021112294279400_BCJ-2021-0615C4","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/HCO.0000000000000292","article-title":"Heart failure with preserved ejection fraction in hypertension","volume":"31","year":"2016","journal-title":"Curr. Opin. Cardiol."},{"key":"2022021112294279400_BCJ-2021-0615C5","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11897-017-0343-y","article-title":"From inflammation to fibrosis-molecular and cellular mechanisms of myocardial tissue remodelling and perspectives on differential treatment opportunities","volume":"14","year":"2017","journal-title":"Curr. Heart Fail. Rep."},{"key":"2022021112294279400_BCJ-2021-0615C6","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s001090050275","article-title":"Cellular mechanisms of cardiac hypertrophy","volume":"76","year":"1998","journal-title":"J. Mol. Med."},{"key":"2022021112294279400_BCJ-2021-0615C7","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1152\/physrev.00054.2009","article-title":"Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale","volume":"90","year":"2010","journal-title":"Physiol. Rev."},{"key":"2022021112294279400_BCJ-2021-0615C8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1749-6632.2009.05088.x","article-title":"Extracellular signal-regulated kinase 1\/2 (ERK1\/2) signaling in cardiac hypertrophy","volume":"1188","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"2022021112294279400_BCJ-2021-0615C9","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1177\/1947601911407323","article-title":"Raf family kinases: old dogs have learned new tricks","volume":"2","year":"2011","journal-title":"Genes Cancer"},{"key":"2022021112294279400_BCJ-2021-0615C10","doi-asserted-by":"publisher","first-page":"26303","DOI":"10.1074\/jbc.270.44.26303","article-title":"Hypertrophic agonists stimulate the activities of the protein kinases c-Raf and A-Raf in cultured ventricular myocytes","volume":"270","year":"1995","journal-title":"J. Biol. Chem."},{"key":"2022021112294279400_BCJ-2021-0615C11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.cellsig.2005.04.005","article-title":"Peptide growth factors signal differentially through protein kinase C to extracellular signal-regulated kinases in neonatal cardiomyocytes","volume":"18","year":"2006","journal-title":"Cell. Signal."},{"key":"2022021112294279400_BCJ-2021-0615C12","doi-asserted-by":"publisher","first-page":"19762","DOI":"10.1074\/jbc.274.28.19762","article-title":"Regulation of Ras.GTP loading and Ras-Raf association in neonatal rat ventricular myocytes by G protein-coupled receptor agonists and phorbol ester. activation of the ERK cascade by phorbol ester is mediated by Ras","volume":"274","year":"1999","journal-title":"J. Biol. Chem."},{"key":"2022021112294279400_BCJ-2021-0615C13","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1172\/JCI200420317","article-title":"Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis","volume":"114","year":"2004","journal-title":"J. Clin. Invest."},{"key":"2022021112294279400_BCJ-2021-0615C14","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1161\/01.CIR.0000138190.50127.6A","article-title":"Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload","volume":"110","year":"2004","journal-title":"Circulation"},{"key":"2022021112294279400_BCJ-2021-0615C15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cvr\/cvv210","article-title":"Cardiac protein kinases: the cardiomyocyte kinome and differential kinase expression in human failing hearts","volume":"108","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"2022021112294279400_BCJ-2021-0615C16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.phrs.2018.08.013","article-title":"Targeting oncogenic Raf protein-serine\/threonine kinases in human cancers","volume":"135","year":"2018","journal-title":"Pharmacol. Res."},{"key":"2022021112294279400_BCJ-2021-0615C17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.gde.2006.12.005","article-title":"New insight into BRAF mutations in cancer","volume":"17","year":"2007","journal-title":"Curr. Opin. Genet. Dev."},{"key":"2022021112294279400_BCJ-2021-0615C18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1615\/CritRevOncog.v17.i1.70","article-title":"Aberrant B-Raf signaling in human cancer - 10 years from bench to bedside","volume":"17","year":"2012","journal-title":"Crit. Rev. Oncog."},{"key":"2022021112294279400_BCJ-2021-0615C19","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1021\/ml4000063","article-title":"Discovery of dabrafenib: a selective inhibitor of Raf kinases with antitumor activity against B-Raf-driven tumors","volume":"4","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"2022021112294279400_BCJ-2021-0615C20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/bjc.2017.399","article-title":"Targeting the Raf kinases in human cancer: the Raf dimer dilemma","volume":"118","year":"2018","journal-title":"Br. J. Cancer"},{"key":"2022021112294279400_BCJ-2021-0615C21","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1042\/CS20210192","article-title":"The anti-cancer drug dabrafenib is not cardiotoxic and inhibits cardiac remodelling and fibrosis in a murine model of hypertension","volume":"135","year":"2021","journal-title":"Clin. Sci. (Lond)"},{"key":"2022021112294279400_BCJ-2021-0615C22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s13059-017-1286-z","article-title":"Natural genetic variation of the cardiac transcriptome in non-diseased donors and patients with dilated cardiomyopathy","volume":"18","year":"2017","journal-title":"Genome Biol."},{"key":"2022021112294279400_BCJ-2021-0615C23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","year":"2014","journal-title":"Genome Biol."},{"key":"2022021112294279400_BCJ-2021-0615C24","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1101\/gad.1516407","article-title":"A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors","volume":"21","year":"2007","journal-title":"Genes Dev."},{"key":"2022021112294279400_BCJ-2021-0615C25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1161\/hh1301.092687","article-title":"Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein","volume":"89","year":"2001","journal-title":"Circ. Res."},{"key":"2022021112294279400_BCJ-2021-0615C26","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1161\/HYPERTENSIONAHA.119.14556","article-title":"Redox regulation of cardiac ASK1 (Apoptosis Signal-regulating Kinase 1) controls p38-MAPK (mitogen-activated protein kinase) and orchestrates cardiac remodeling to hypertension","volume":"76","year":"2020","journal-title":"Hypertension"},{"key":"2022021112294279400_BCJ-2021-0615C27","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1042\/BCJ20210144","article-title":"The insulin receptor family and protein kinase B (Akt) are activated in the heart by alkaline pH and (\u03b11-adrenergic receptors","volume":"478","year":"2021","journal-title":"Biochem. J."},{"key":"2022021112294279400_BCJ-2021-0615C28","doi-asserted-by":"publisher","first-page":"e10027","DOI":"10.1371\/journal.pone.0010027","article-title":"ERK1\/2 signaling dominates over rhoA signaling in regulating early changes in RNA expression induced by endothelin-1 in neonatal rat cardiomyocytes","volume":"5","year":"2010","journal-title":"PLoS ONE"},{"key":"2022021112294279400_BCJ-2021-0615C29","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1128\/MCB.21.4.1173-1184.2001","article-title":"Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein, Rac1","volume":"21","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"2022021112294279400_BCJ-2021-0615C30","doi-asserted-by":"publisher","first-page":"H1671","DOI":"10.1152\/ajpheart.01155.2009","article-title":"Cre-loxP DNA recombination is possible with only minimal unspecific transcriptional changes and without cardiomyopathy in Tg(alphaMHC-MerCreMer) mice","volume":"299","year":"2010","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2022021112294279400_BCJ-2021-0615C31","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1038\/s41598-018-24085-9","article-title":"Refined protocols of tamoxifen injection for inducible DNA recombination in mouse astroglia","volume":"8","year":"2018","journal-title":"Sci. Rep."},{"key":"2022021112294279400_BCJ-2021-0615C32","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1042\/BJ20110289","article-title":"Regulation and function of the RSK family of protein kinases","volume":"441","year":"2012","journal-title":"Biochem. J."},{"key":"2022021112294279400_BCJ-2021-0615C33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.biocel.2010.09.018","article-title":"Functions and regulation of the 70 kDa ribosomal S6 kinases","volume":"43","year":"2011","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"2022021112294279400_BCJ-2021-0615C34","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.bbamcr.2011.03.013","article-title":"Interplay between FOXO, TOR, and Akt","volume":"1813","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"2022021112294279400_BCJ-2021-0615C35","doi-asserted-by":"publisher","first-page":"R32","DOI":"10.1186\/gb-2008-9-2-r32","article-title":"Temporal regulation of expression of immediate early and second phase transcripts by endothelin-1 in cardiomyocytes","volume":"9","year":"2008","journal-title":"Genome Biol."},{"key":"2022021112294279400_BCJ-2021-0615C36","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1042\/BJ20121371","article-title":"P90 ribosomal S6 kinases play a significant role in early gene regulation in the cardiomyocyte response to Gq protein-coupled receptor stimuli, endothelin-1 and (\u03b11-adrenergic receptor agonists","volume":"450","year":"2013","journal-title":"Biochem. J."},{"key":"2022021112294279400_BCJ-2021-0615C37","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature24676","article-title":"IL-11 is a crucial determinant of cardiovascular fibrosis","volume":"552","year":"2017","journal-title":"Nature"},{"key":"2022021112294279400_BCJ-2021-0615C38","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1038\/onc.2012.330","article-title":"ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers","volume":"32","year":"2012","journal-title":"Oncogene"},{"key":"2022021112294279400_BCJ-2021-0615C39","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1006\/jmcc.1996.0163","article-title":"Rapid transition of cardiomyocytes from hyperplasia to hypertrophy during postnatal development","volume":"28","year":"1996","journal-title":"J. Mol. Cell. Cardiol."},{"key":"2022021112294279400_BCJ-2021-0615C40","doi-asserted-by":"publisher","first-page":"e07455","DOI":"10.7554\/eLife.07455","article-title":"Reduced matrix rigidity promotes neonatal cardiomyocyte dedifferentiation, proliferation and clonal expansion","volume":"4","year":"2015","journal-title":"eLife"},{"key":"2022021112294279400_BCJ-2021-0615C41","doi-asserted-by":"publisher","first-page":"11100","DOI":"10.1158\/0008-5472.CAN-06-2554","article-title":"Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885","volume":"66","year":"2006","journal-title":"Cancer Res."},{"key":"2022021112294279400_BCJ-2021-0615C42","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1042\/bj3510095","article-title":"Specificity and mechanism of action of some commonly used protein kinase inhibitors","volume":"351","year":"2000","journal-title":"Biochem. J."},{"key":"2022021112294279400_BCJ-2021-0615C43","doi-asserted-by":"publisher","first-page":"100795","DOI":"10.1016\/j.tranon.2020.100795","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"13","year":"2020","journal-title":"Transl. Oncol."},{"key":"2022021112294279400_BCJ-2021-0615C44","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jacbts.2017.07.013","article-title":"Murine models of heart failure with preserved ejection fraction: a \u2018fishing expedition\u2019","volume":"2","year":"2017","journal-title":"JACC Basic Transl. Sci."},{"key":"2022021112294279400_BCJ-2021-0615C45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0014-5793(93)81291-7","article-title":"Endothelin-1, phorbol esters and phenylephrine stimulate MAP kinase activities in ventricular cardiomyocytes","volume":"317","year":"1993","journal-title":"FEBS Lett."},{"key":"2022021112294279400_BCJ-2021-0615C46","doi-asserted-by":"publisher","first-page":"6341","DOI":"10.1093\/emboj\/19.23.6341","article-title":"The MEK1-ERK1\/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice","volume":"19","year":"2000","journal-title":"EMBO J."},{"key":"2022021112294279400_BCJ-2021-0615C47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1161\/CIRCRESAHA.110.231514","article-title":"Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth","volume":"108","year":"2011","journal-title":"Circ. Res."},{"key":"2022021112294279400_BCJ-2021-0615C48","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1080\/02699050500284218","article-title":"The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions","volume":"24","year":"2006","journal-title":"Growth Factors"},{"key":"2022021112294279400_BCJ-2021-0615C49","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cardiores.2004.02.003","article-title":"Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy","volume":"63","year":"2004","journal-title":"Cardiovasc. Res."},{"key":"2022021112294279400_BCJ-2021-0615C50","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcdb.2016.01.009","article-title":"The regulation of oncogenic Ras\/ERK signalling by dual-specificity mitogen activated protein kinase phosphatases (MKPs)","volume":"50","year":"2016","journal-title":"Semin. Cell Dev. Biol."},{"key":"2022021112294279400_BCJ-2021-0615C51","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.cellsig.2010.10.024","article-title":"Monophosphothreonyl extracellular signal-regulated kinases 1 and 2 (ERK1\/2) are formed endogenously in intact cardiac myocytes and are enzymically active","volume":"23","year":"2011","journal-title":"Cell Signal."},{"key":"2022021112294279400_BCJ-2021-0615C52","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1091\/mbc.E15-07-0527","article-title":"Regulatory roles of conserved phosphorylation sites in the activation T-loop of the MAP kinase ERK1","volume":"27","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"2022021112294279400_BCJ-2021-0615C53","doi-asserted-by":"publisher","DOI":"10.1101\/2021.11.05.467491","article-title":"Regulation of ERK2 activity by dynamic S-acylation","year":"2021","journal-title":"BioRXiv"},{"key":"2022021112294279400_BCJ-2021-0615C54","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1038\/nature07511","article-title":"MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts","volume":"456","year":"2008","journal-title":"Nature"},{"key":"2022021112294279400_BCJ-2021-0615C55","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.bbamcr.2006.11.003","article-title":"The integration of signaling by multiprotein complexes containing Raf kinases","volume":"1773","year":"2007","journal-title":"Biochim. Biophys. Acta"},{"key":"2022021112294279400_BCJ-2021-0615C56","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/jcp.21094","article-title":"Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses","volume":"212","year":"2007","journal-title":"J. Cell Physiol."},{"key":"2022021112294279400_BCJ-2021-0615C57","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ejhf.62","article-title":"Targeting myocardial remodelling to develop novel therapies for heart failure: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology","volume":"16","year":"2014","journal-title":"Eur. J. Heart Fail."},{"key":"2022021112294279400_BCJ-2021-0615C58","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/nrd3252","article-title":"Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes","volume":"10","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"2022021112294279400_BCJ-2021-0615C59","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.hfc.2016.12.004","article-title":"Management of heart failure in cancer patients and cancer survivors","volume":"13","year":"2017","journal-title":"Heart Fail. Clin."},{"key":"2022021112294279400_BCJ-2021-0615C60","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s12012-017-9425-z","article-title":"Cardiovascular effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism","volume":"17","year":"2017","journal-title":"Cardiovasc. Toxicol."},{"key":"2022021112294279400_BCJ-2021-0615C61","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.pharmthera.2018.06.017","article-title":"Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors","volume":"192","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"2022021112294279400_BCJ-2021-0615C62","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1200\/JGO.2015.000802","article-title":"Risk of selected cardiovascular toxicities in patients with cancer treated with MEK inhibitors: a comparative systematic review and meta-analysis","volume":"1","year":"2015","journal-title":"J. Glob. Oncol."},{"key":"2022021112294279400_BCJ-2021-0615C63","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1517\/14656566.2012.737780","article-title":"Vemurafenib for the treatment of melanoma","volume":"13","year":"2012","journal-title":"Expert Opin. Pharmacother."},{"key":"2022021112294279400_BCJ-2021-0615C64","doi-asserted-by":"publisher","first-page":"e198890","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis","volume":"2","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"2022021112294279400_BCJ-2021-0615C65","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1002\/cam4.3938","article-title":"Cardiovascular adverse events associated with BRAF versus BRAF\/MEK inhibitor: cross-sectional and longitudinal analysis using two large national registries","volume":"10","year":"2021","journal-title":"Cancer Med."}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/479\/3\/401\/928929\/bcj-2021-0615.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/479\/3\/401\/928929\/bcj-2021-0615.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T07:30:36Z","timestamp":1644564636000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/479\/3\/401\/230788\/Cardiomyocyte-BRAF-and-type-1-RAF-inhibitors"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,11]]},"references-count":65,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,2,11]]}},"URL":"https:\/\/doi.org\/10.1042\/bcj20210615","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.08.14.455637","asserted-by":"object"}]},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,11]]}}}